Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. covers the month of December 2019, specifically dated December 11, 2019. The filing serves to report a material corporate event regarding the Company's clinical development program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a clinical milestone rather than a financial statement.
Material Changes
The primary material change reported is the initiation of the Phase 1/2 Aurora Trial for the Company's investigational therapy, QR-1123. On December 11, 2019, the Company announced that the first patient was dosed in this trial, which targets Autosomal Dominant Retinitis Pigmentosa (adRP).
Guidance, Outlook, and Risks
The filing incorporates by reference a press release detailing the clinical milestone. No specific financial guidance, management commentary on future financial performance, or discussion of risks and contingencies is included in the body of this specific Form 6-K text.
Key Facts for Investor Verification
- First patient dosed in the Phase 1/2 Aurora Trial for QR-1123 on December 11, 2019.
- The trial targets Autosomal Dominant Retinitis Pigmentosa (adRP).
- The full details of the announcement are contained in the attached press release (Exhibit 99.1).
- This filing incorporates the information into the Company's registration statement on Form F-3 (File No. 333-228251).